



Declaration for Patent Application

Ducket Number: 1975.0180003/TJS

As a belo	ow named inventor, I hereby	declare that:					
My residence, mailing address and citizenship are as stated below next to my name.							
I believe I am an original, first and joint inventor of the subject matter that is claimed and for which a patent is sought on the invention entitled Fusion Constructs and Use of Same to Produce Antibodies With Increased Fc Receptor Binding Affinity and Effector Function, the specification of which is attached hereto unless the following box is checked:							
\boxtimes	was filed onJanuary 22,	2004	;		•		
	as United States Application	on Number or PC	l'International A	pplication Number <u>10/76</u>	1.435	; and	
	was amended on		_(if applicable).				
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.							
I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.							
I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f) or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application, which designated at least one country other than the United States of America, listed below, and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or PCT international application having a filing date before that of the application on which priority is claimed.							
Prior For	eign Applications(s):				Priorit	/ Claimed	
(Applica	tion No.)	(Country)		(Day/Month/Year Filed)	_ · □Yes	□ No	
(Applica	tion No.)	(Country)		(Day/Month/Year Filed)	_ Yes	□ No	
Send Correspondence to: STERNE, KESSLER, GOLDSTEIN & Fox P.L.L.C. 1100 New York Avenue, N.W. Washington, D.C. 20005-3934							
Direct To	dephone Calls to:	((202) 371-2600				

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

	Full name of first Inventor:	Pablo Umaña	
	Signature of first Inventor:	Loke 18	Date: 5, 8, 04
	Residence:	Zurich;-SWITZERLAND	
	Citizenship:	Costa Rica	
૧.૫. દ્રાક્ષાન્મ	Mailing Address:	- Keeferholzstrause 262 - Zürich, SWITZERLAND CH-8046	Freistrasse 159 Zünich, Switzerland CH-80
	·		
	Full name of second Inventor:	Peter Bruenker	
	Signature of second Inventor.	The Faller	Date: C, A, 04
	Residence:	Hitmau, SWITZERLAND	
	Citizenship:	Germany	
	Mailing Address:	Burgwiesenstrasse 3C Hittnau, SWITZERLAND CH-8335	
	Full name of third Inventor:	Claudia Ferrara	
	Signature of third inventor:	Clarky Ferone	Date: 5/8/04
	Residence:	Zürich, SWITZERLAND	
	Citizenship:	Switzerland	
	Mailing Address:	Hallwylstrasse 27 Zürich, SWITZERLAND CH-8004	

Full name of fourth inventor:	Tobias Suter	
Signature of fourth Inventor:	J. hyes	Date: 4. 8.7004
Residence:	Baden, SWITZERLAND	
Citizenship:	Switzerland	
Mailing Address:	Weite Gasse 13 Baden, SWITZERLAND CH-5400	



COPY

POWER OF ATTORNEY FROM ASSIGNEE

GlycArt Biotechnology AG, a corporation of Switzerland, having a principal place of business at Wagistrasse 18, Schlieren-Zürich, Switzerland CH-8952, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on (1) 5/6/4, (2) 5/6/4, (3) 5Aug. O4 and (4) 4Aug. C4 of an invention known as Fusion Constructs and Use of Same to Produce Antibodies With Increased Fc Receptor Binding Affinity and Effector Function (Attorney Docket No.1975.0180003/TJS), that is disclosed and claimed in a patent application of the same title by the inventors (1) Pablo Umaña, (2) Peter Bruenker, (3) Claudia Ferrara and (4) Tobias Suter (said application filed on January 22, 2004 at the U.S. Patent and Trademark Office, having Application Number 10/761,435).

For the purpose of PAIR, the Customer Number is 26111.

The Assignee hereby appoint the U.S. attorneys associated with CUSTOMER NUMBER 28393 to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Esq., Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michael A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokahl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 33,876; Robert C. Millonig, Esq., Registration No. 34,395; Michael V. Messinger, Esq., Registration No. 37,575; Judith U. Kim, Bsq., Registration No. 40,679; Timothy J. Shea, Jr., Esq., Registration No. 41,306; Patrick B. Garrett, Esq., Registration No. 39,987. The Assignees hereby grant said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

Customer Number 26111
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: GivcArt Biotechnology AG

BY: Pabo Umiera

JOEL DEAU-MAGET

TITLE:

4 Loust 5, 250 4

Quant 5, 2004

228798_1.DOC



COPY

PTO/SB/88 (18-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Papenwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB central number.

1975.0180003/TJS STATEMENT UNDER 37 CFR 3.73(b) Applicant/Patent Owner: UMAÑA et al. Filed/Issue Date: January 22, 2004 10/761.435 Application No./Patent No.: __ Entitled: See 1 in Addendum corporation GlycArt Biotechnology AG (Type of Assignee, e.g., corporation, partnership, university, government exency, etc.) (Name of Assignee) states that it is: 1. 3 the assignee of the entire right, title, and interest; or 2. I an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is --- % in the patent application patent Identified above by virtue of either. A. [x] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel e copy thereof is lattached. OR B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current :woled nworks as eangissa To: -The document was recorded in the Patent and Trademark Office at , or for which a copy thereof is attached. , Frame Regi 2. From: The document was recorded in the Patent and Trademark Office at , or for which a copy thereof is attached. Frame 3. From: The document was recorded in the Patent and Trademark Office at _, Frame _ , or for which a copy thereof is attached. [] Additional documents in the chain of title are listed on a supplemental sheet. [X] Copies of assignments or other documents in the chain of title are attached. INOTE: A separate copy (i.e., the original essignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302.08) The undersigned (whose title is supplied below) is authorized to act on behalf of the assignes. Ho Umaña Typed or printed name 755-Talaphona number Signature csQCEO Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or rotain a benefit by the public which is to die (and by the USPTO to process) an application. Confidentiatily is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed speciation form to the USPTO. Three will vary depending spon the individual case. Any comments on the amount of the you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tredemark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEEB OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Addendum

1. FUSION CONSTRUCTS AND USE OF SAME TO PRODUCE ANTIBODIES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION & EFFECTOR FUNCTION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: (1) Pable Umaña, (2) Peter Bruenker, (3) Claudia Ferrara and (4) Tobias Suter, the undersigned inventors hereby sell and assign to GlycArt Biotechnology AG, a corporation formed under the laws of Switzerland (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

Aug. 5, 2004

Aug. 4, 2004 —

(a) in the invention(s) known as Fusion Constructs and Use of Same to Produce Antibodies With increased Fc Receptor Binding Affinity and Effector Function for which application(s) for patent in the United States of America has (have) been executed by the undersigned on (1) 300, 21, 2004(2)

21/1/014 (3) 27/1/014 and (4) 21/1/014 (also known as United States Application No. 10/761,435, filed January 22, 2004), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

Aug. 5, 2004

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which my such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assigner had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any nonprovisional, continuing (continuation, divisional, or continuation-in-part), relissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), relessue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Robert Greene Sterne, Esq., Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Comwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michele A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Bsq., Registration No. 33,997; Robert B. Soltohl, Esq., Registration No. 36,013; Eric K. Steffe, Bsq., Registration No. 36,688; Michael Q. Lee, Bsq., Registration No. 35,239; Stoven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 33,876; Robert C. Millonig, Esq., Registration No. 34,395; Michael V. Messinger, Esq., Registration No. 37,975; Judith U. Kim, Esq., Registration No. 40,679; Timothy J. Shen, Jr., Esq., Registration No. 41,306; Patrick B. Garrett, Esq., Registration No. 39,987; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or destrable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

TO ASSIGNMENT BRANCH NOT FOR RECORDATION DO NOT FORWARD

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

N WITNESS WHEREOF, executed by the undersigned inventors on the date opposite higher name.

Date: 5, 8, 64

Signature of Inventor: Pablo Umans

Peter Bruenker

Date: 5, 8, 2004

Signature of Inventor: Claudia Ferrara

Date: 4,8-7004

Signature of Inventor: Table 5.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.